Scholar Rock Braces for Approval Clarity but Commercial Questions Linger

Scholar Rock Holding Corporation reports first-quarter 2026 earnings before the market opens on May 7, 2026, with analysts expecting a loss of $0.82 per share. The central question for investors: can the clinical-stage biopharmaceutical company demonstrate progress in its Phase 3 apitegromab program for spinal muscular atrophy while managing its cash runway, or will widening losses and regulatory uncertainties weigh on sentiment? With 17 of 18 analysts rating the stock a Strong Buy and shares trading near analyst price targets, this report will test whether the bullish thesis remains intact.

Part 1: Earnings Preview

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company focused on developing apitegromab, a novel therapy targeting myostatin for the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases. The company's proprietary platform targets growth factors in the TGFβ protein superfamily, representing a fundamentally different approach to muscle-wasting conditions. For investors, Scholar Rock's value hinges entirely on clinical trial success, regulatory progress, and the ability to extend its cash runway toward commercialization.

For the first quarter of 2026, analysts expect Scholar Rock to report a loss of $0.82 per share when results are released before the market opens on May 7, 2026. The company most recently reported a loss of $0.88 per share for the fourth quarter of 2025. Compared to the same quarter last year, when Scholar Rock posted a loss of $0.67 per share, the consensus estimate represents a 22.39% increase in losses year-over-year, reflecting elevated R&D spending as the company advances its pipeline.

Three key themes define this earnings story. Clinical Trial Progress and Data Readouts remain the primary focus—investors will scrutinize any updates on the Phase 3 SAPPHIRE trial for apitegromab in SMA, including enrollment milestones, safety data, and anticipated timelines for topline results. Regulatory Pathway and FDA Interactions represent the second critical area, as any guidance on submission timelines, regulatory feedback, or potential accelerated approval pathways could significantly impact the stock. Cash Runway and Burn Rate round out the narrative, with investors closely monitoring quarterly R&D expenditures, operating expenses, and management's updated guidance on how long current cash reserves will fund operations before additional financing is required.

Analyst commentary ahead of the release emphasizes cautious optimism. The Street remains overwhelmingly bullish on Scholar Rock's long-term potential, with the company positioned as a leader in myostatin biology and apitegromab representing a potentially transformative therapy for SMA patients. However, analysts acknowledge near-term headwinds including the lack of revenue, increasing cash burn, and execution risk inherent in late-stage clinical development. The consensus view suggests that positive clinical updates or regulatory progress could drive significant upside, while any setbacks in trial timelines or safety signals could trigger sharp downside volatility.

Part 2: Historical Earnings Performance

Scholar Rock has demonstrated a consistent pattern of missing earnings estimates over the past four quarters, though the magnitude of misses has moderated recently. In Q1 2025, the company reported a loss of $0.67 per share against expectations of $0.63, missing by 6.35%. The Q2 2025 report marked the most significant disappointment, with a loss of $0.98 per share versus the $0.66 estimate—a substantial 48.48% miss that reflected higher-than-anticipated R&D spending. Performance improved in the second half of 2025, with Q3 showing a $0.90 loss against an $0.88 estimate (a 2.27% miss) and Q4 posting a $0.88 loss versus an $0.86 estimate (a 2.33% miss).

The trend reveals a company that has struggled to control operating expenses relative to analyst expectations, particularly during periods of intensive clinical trial activity. The dramatic Q2 miss appears to have been an inflection point, after which both the company and analysts recalibrated expectations for elevated spending. The subsequent two quarters showed much tighter alignment between actual results and estimates, suggesting improved visibility into the cost structure of advancing apitegromab through late-stage development. For the upcoming Q1 2026 report, the $0.82 consensus estimate implies analysts expect continued elevated spending but with better predictability than the volatile pattern seen in the first half of 2025.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Scholar Rock typically reports earnings before the market opens, meaning Day 0 represents the first trading session where investors can react to results, while Day +1 captures follow-through momentum.

Historical price behavior around Scholar Rock earnings reveals significant volatility, with the stock prone to dramatic swings in both directions. The most recent report on March 3, 2026 produced a modest 1.91% gain on Day 0 followed by a stronger 7.04% rally on Day +1, suggesting positive investor reception despite the earnings miss. The November 2025 report triggered the most extreme reaction in the dataset—a massive 24.41% surge on Day 0, though this was followed by a 2.51% pullback the next session as some gains were taken.

The pattern shows considerable variability, with Day 0 moves ranging from a 6.40% decline (August 2025) to the 24.41% spike (November 2025). Across the eight most recent reports, the average absolute Day 0 move stands at 5.88%, while Day +1 follow-through averages 4.40%—both figures indicating substantial post-earnings volatility. Intraday trading ranges are even more pronounced, averaging 10.60% on Day 0 and 7.09% on Day +1, reflecting the speculative nature of the stock and the binary outcomes often associated with clinical-stage biotech companies. Investors should prepare for significant price movement in either direction, with the magnitude likely determined by any clinical or regulatory updates accompanying the financial results.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.46% expected move for this earnings release, implying a trading range between $43.12 and $51.10. This expected move is notably higher than the 5.88% average Day 0 move observed historically, suggesting options traders are anticipating above-average volatility—possibly due to expectations for meaningful clinical or regulatory updates beyond routine financial results.

Part 3: What Analysts Are Saying

Analyst sentiment on Scholar Rock remains overwhelmingly bullish heading into the Q1 2026 earnings report. The consensus rating stands at 4.89 out of 5.0, with 17 of 18 analysts rating the stock a Strong Buy, while just one analyst maintains a Hold rating. Not a single analyst rates Scholar Rock a Sell or Strong Sell, reflecting broad conviction in the company's long-term potential despite its pre-revenue status and ongoing losses.

The average price target of $57.73 implies 22.5% upside from the current price of $47.11, with individual targets ranging from a low of $48.00 to a high of $70.00. This wide range reflects differing assumptions about clinical trial success probabilities, regulatory timelines, and eventual market penetration for apitegromab. The sentiment trend has improved over the past month, with one additional analyst upgrading to Strong Buy, bringing the total from 16 to 17. The average recommendation also ticked up from 4.88 to 4.89, indicating incrementally more bullish positioning.

The near-unanimous Strong Buy consensus suggests the Street views Scholar Rock's risk-reward profile as highly favorable at current levels, with the potential for apitegromab to address a significant unmet need in SMA justifying the clinical and regulatory risks. However, the single Hold rating serves as a reminder that execution remains critical, and any stumbles in the Phase 3 program could quickly shift sentiment. The clustering of price targets in the high $50s to low $60s indicates analysts expect meaningful appreciation if the company continues to hit clinical milestones, while the $70 high-end target reflects the blue-sky scenario of accelerated approval and strong commercial uptake.

Part 4: Technical Picture

The Barchart Technical Opinion for Scholar Rock shows a Buy signal at 88%, unchanged from both one week ago and one month ago, indicating stable technical momentum heading into earnings. The stock is currently trading at $47.11, positioned above its 200-day moving average of $40.24, which confirms the longer-term uptrend remains intact despite recent consolidation.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum is positive but not overwhelming, reflecting recent sideways trading
• Medium-term (100% Buy): Strong buy signal indicates solid intermediate-term momentum supports the current trend
• Long-term (100% Buy): Strong buy signal confirms the longer-term uptrend remains firmly established

Trend Characteristics: The combination of Good strength and Average direction suggests Scholar Rock is in a constructive uptrend but lacks the explosive momentum seen in some growth stocks, creating a measured technical backdrop heading into earnings.

The stock is trading above its 5-day ($46.74), 10-day ($46.70), 50-day ($46.08), 100-day ($45.69), and 200-day ($40.24) moving averages, but has slipped below its 20-day moving average ($47.89), indicating short-term consolidation within a broader uptrend.

Key technical levels to watch include resistance at the 20-day moving average of $47.89, which the stock is currently testing from below, and support at the 50-day moving average of $46.08. The stock's position above all major long-term moving averages provides a supportive technical foundation heading into earnings, though the recent pullback below the 20-day average suggests some near-term caution. The overall setup is moderately constructive—the longer-term trend remains positive, but the lack of strong short-term momentum means the stock could move sharply in either direction depending on the content of the earnings report and any clinical updates. Given the historical volatility around Scholar Rock earnings and the options market pricing in an above-average move, traders should expect significant price action regardless of direction.